shlokn/autogkb huggingface dataset:
Article: IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients
Gene: IFNL3, IFNL4
Variant/haplotype: rs12979860
Drug(s): peginterferon alfa-2a, peginterferon alfa-2b, ribavirin
Phenotype category: Efficacy
Significant: no
Association: Genotype CC is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.
Notes: No significant effect of this SNP on null-R (not achieving a hepatitis C virus (HCV) RNA drop of >= 1 log at week 4) was seen; logistic regression analysis.
Article: Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder
Gene: HTT
Variant/haplotype: rs362272
Drug(s): methylphenidate
Phenotype category: Efficacy
Significant: no
Association: Allele G is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.
Notes: The authors carried out a GWAS in a Spanish cohort of pediatric patients, than performed a meta-analysis using data from the Spanish cohort and data from a Brazilian adult patient cohort.; This variant was not significant in the meta-analysis after Bonferroni correction had been applied, and was nominally significant (i.e did not reach genome-wide significance) in the initial GWAS in the Spanish cohort.; Response was measured on the Clinical Global Impression-Improvement scale (CGI-I). A CGI-I score of two points or less after eight weeks of treatment was considered a good response.
Article: CYP2B6 Genotype Guided Dosing of Propofol Anesthesia in the Elderly based on Nonparametric Population Pharmacokinetic Modeling and Simulations
Gene: CYP2B6
Variant/haplotype: rs2279343
Drug(s): propofol
Phenotype category: Metabolism/PK
Significant: yes
Association: Genotypes AA + AG is associated with decreased clearance of propofol as compared to genotype GG.
Notes: Population pharmacokinetic modeling. Patients with the AA or AG genotype had a significantly decreased elimination rate from the central compartment (Ke) as compared to those with the GG genotype. Patients with the AA or AG genotype also had a decreased clearance of propofol as compared to those with the GG genotype, though no statistical information was provided. Propofol anesthesia.
Article: A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis
Gene: TNF
Variant/haplotype: rs1799724
Drug(s): adalimumab
Phenotype category: Efficacy
Significant: no
Association: Genotype CC is not associated with response to adalimumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.
Notes: No significant difference in genotype frequencies was seen between those who were responders to treatment and those who were non-responders. Response defined as a 50% percent response to adalimumab therapy according to the American College of Rheumatology criteria (ACR50 responders) at week 12 after treatment initiation.
Article: Correlation of MDR1 gene polymorphisms with anesthetic effect of sevoflurane–remifentanil following pediatric tonsillectomy
Gene: ABCB1
Variant/haplotype: rs1128503
Drug(s): remifentanil, sevoflurane
Phenotype category: Efficacy
Significant: yes
Association: Genotype GG is associated with increased response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.
Notes: The GG genotype was associated with a decreased visual analog scale score at 1, 2, 4, and 8 hours post-operative (all P<.05).; The GG genotype was associated with shorter times of induction, respiration recovery, eyeopening,; and extubation (all P<.05).; Ramsay sedation scores were lower in the GG genotype (less sedation), while Face, Legs, Activity, Cry, Consolability scale (FLACC) scores were higher (increased pain) (both P<.05).
Article: Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population
Gene: ERCC1
Variant/haplotype: rs2298881
Drug(s): Platinum compounds
Phenotype category: Efficacy
Significant: no
Association: Genotypes AA + AC is not associated with increased clinical benefit to Platinum compounds in people with Neoplasms as compared to genotype CC.
Notes: Authors perform meta-analysis using several models looking at response and OS and subgroup analysis by cancer type.
Article: Genome-wide Association Study of Virologic Response with Efavirenz- or Abacavir-containing Regimens in AIDS Clinical Trials Group Protocols
Gene: CYP2B6
Variant/haplotype: rs4803419
Drug(s): efavirenz
Phenotype category: Efficacy
Significant: no
Association: Allele C is not associated with response to efavirenz in people with HIV Infections as compared to allele T.
Notes: No significant association with virologic failure is found for the combinations of CYP2B6 polymorphisms (rs3745274, rs28399499, and rs4803419).
Article: Variants in the CYP2B6 3′UTR alter in vitro and in vivo CYP2B6 activity: potential role of microRNAs
Gene: CYP2B6
Variant/haplotype: rs70950385
Drug(s): efavirenz
Phenotype category: Metabolism/PK
Significant: yes
Association: Genotype CA/CA is associated with decreased metabolism of efavirenz in healthy individuals as compared to genotype AG/AG.
Notes: The rs70950385 and rs1042389 variant alleles were associated with a decrease in CYP2B6 activity when comparing Plasma efavirenz AUC0-48 ratios (8-OH-EFV/EFV)) between AG/AG and CA/CA genotypes (32.7%; p<0.05).
Article: CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer
Gene: CYP2D6
Variant/haplotype: CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41
Drug(s): endoxifen
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.
Notes: No information on menopausal status or if tamoxifen only treatment. No co-treatment with CYP2D6 inhibitors CYP2D6 alleles *2, *3, *4, *5, *6, *10, and *41 are genotyped with predeveloped TaqMan Genotyping Assays. Genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2 -*1/*1, *1/*2, *2/*2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41-*1/*10, *2/*10, *1/*41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6-*10/*10, *10/*41, *1/*5, *2/*5, *5/*10). [pre-menopausal][post-menopausal] [adjuvant]  [DNA source: leukocytes] [HWE: Vietnamese *1, 2, 4, 5, 10, 41 yes Filipino *1 and *2 no rest yes] An additional nested case-control study (n=48) showed an  increased risk of recurrence at low and high (>70 ng/ml) endoxifen concentrations.
Article: Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement
Gene: CYP2C9
Variant/haplotype: CYP2C9*2, CYP2C9*3
Drug(s): fluindione
Phenotype category: Metabolism/PK
Significant: no
Association: CYP2C9 *2 + *3 is not associated with dose of fluindione in children as compared to CYP2C9 *1/*1.
Article: Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy
Gene: CYP3A5
Variant/haplotype: CYP3A5*1, CYP3A5*3
Drug(s): carbamazepine
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP3A5 *3/*3 is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to CYP3A5 *1/*1 + *1/*3.
Notes: as measured by a greater half-life. This association was only significant in the African American sub-cohort and not in Caucasian patients. The *3 allele occurred at a lower frequency in African Americans compared to Caucasians.
Article: Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV
Gene: UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9
Variant/haplotype: rs10929302
Drug(s): tenofovir
Phenotype category: Metabolism/PK
Significant: no
Association: Allele A is not associated with clearance of tenofovir in people with HIV Infections as compared to allele G.
Notes: Significance threshold was set at 4.5E-3.
Article: Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy
Gene: CYP2C9
Variant/haplotype: CYP2C9*1, CYP2C9*2, CYP2C9*3
Drug(s): phenytoin
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP2C9 *1/*3 + *2/*3 are associated with increased concentrations of phenytoin in children with as compared to CYP2C9 *1/*1 + *1/*2.
Notes: Patients who were heterozygous for the CYP2C9*3 allele had significantly higher levels of phenytoin than patients who did not carry the *3 allele. No patients with the *3/*3 diplotype were identified.
Article: Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects
Gene: SLC6A3
Variant/haplotype: rs2652511
Drug(s): methylphenidate
Phenotype category: Efficacy
Significant: no
Association: Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.
Notes: Clinical Global Impression-Severity (CGI-S) scale and the Children’s Global Assessment Scale (CGAS).
Article: A Candidate Gene Analysis of Methylphenidate Response in Attention-Deficit/Hyperactivity Disorder
Gene: SNAP25
Variant/haplotype: rs1051312
Drug(s): methylphenidate
Phenotype category: Efficacy
Significant: no
Association: Allele C is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele T.
Article: An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3′-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients
Gene: NR1I2
Variant/haplotype: rs3732360
Drug(s): efavirenz
Phenotype category: Metabolism/PK
Significant: no
Association: Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.
Article: The Pharmacogenetics of Cannabis in the Treatment of Chronic Pain
Gene: ABCB1
Variant/haplotype: rs1045642
Drug(s): cannabinoids
Phenotype category: Efficacy
Significant: yes
Association: Genotypes AG + GG is associated with increased clinical benefit to cannabinoids in people with Pain as compared to genotype AA.
Notes: "CC homozygous patients and CT heterozygotes for the ABCB1 gene were associated with an average pain reduction of approximately 2 VAS points, compared to the 1.3 VAS points of TT homozygotes."
Article: Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients
Gene: GGCX
Variant/haplotype: rs699664
Drug(s): warfarin
Phenotype category: Dosage
Significant: no
Association: Allele T is not associated with dose of warfarin as compared to allele C.
Article: Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics
Gene: CYP3A4
Variant/haplotype: CYP3A4*1, CYP3A4*3
Drug(s): quetiapine
Phenotype category: Metabolism/PK
Significant: not stated
Association: CYP3A4 *1/*3 is associated with increased concentrations of quetiapine in healthy individuals as compared to CYP3A4 *1/*1.
Notes: CYP3A4 *1/*3 subject (n=1) showed a higher quetiapine dose/weight-adjusted AUC and t1/2 compared to the mean of the CYP3A4*1/*1 subjects.
Article: CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients
Gene: UGT1A9
Variant/haplotype: rs6714486
Drug(s): mycophenolic acid
Phenotype category: Metabolism/PK
Significant: yes
Association: Genotypes AA + AT is associated with decreased dose-adjusted trough concentrations of mycophenolic acid in children with Kidney Transplantation as compared to genotype TT.
Notes: "patients carrying the UGT1A9-275A variant allele had lower AUC0–12h/MPA-D (0.053 [IQR 0.040–0.100] ug*hr/ml/mg/m2) than patients carrying only the UGT1A9-275T ancestral allele genotype (0.117 [IQR 0.058–0.150]ug*hr/ml/mg/m2) with a difference of marginal significance "
Article: Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model
Gene: AGTR1
Variant/haplotype: rs5182
Drug(s): perindopril
Phenotype category: Efficacy
Significant: yes
Association: Genotypes CC + CT is associated with decreased response to perindopril in people with Coronary Artery Disease as compared to genotype TT.
Notes: Three SNPS are combined for a risk score ranging between 0 and 6: rs275651, rs5182, and rs12050217. Patients with risk scores of 0 and 1 and treated with perindopril had absolute risk reductions of 7.50% (95% CI: 3.69-11.73) and 4.30% (95% CI: 2.00-6.53), respectively. Nonsignificant estimated absolute risk increase of 1.32% was observed in patients with a PGXscore >=3. Lower risk score had better response to treatment by primary endpoint of cardiovascular mortality, nonfatal MI, and resuscitated cardiac arrest. Part of PERGENE trial for cardiovascular outcomes.
Article: Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study
Gene: GRAMD1B
Variant/haplotype: rs61123830
Drug(s): lithium
Phenotype category: Efficacy
Significant: yes
Association: Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.
Article: Pharmacogenetic Predictors of Methylphenidate Dose-Response in Attention-Deficit/Hyperactivity Disorder
Gene: ADRA2A
Variant/haplotype: rs1800544
Drug(s): methylphenidate
Phenotype category: Efficacy
Significant: not stated
Association: Genotype GG is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CC + CG.
Notes: Vanderbilt ADHD Parent Rating Scales and Vanderbilt ADHD Teacher Rating Scales - hyperactive-impulsive domain score was derived by totaling scores from the nine hyperactive-impulsive symptoms. A main effect on hyperactive-impulsive domain scores was detected for the ADRA2A polymorphism ( p = .003), with G homozygotes displaying higher symptom levels on placebo and continuing at these higher levels as MPH doses increased.  The ADRA2A-by-dose interaction fell short of the threshold for statistical significance ( p > .025) with a p=0.03.
Article: Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
Gene: CYP2C19
Variant/haplotype: CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17
Drug(s): clopidogrel
Phenotype category: Efficacy, Metabolism/PK
Significant: yes
Association: CYP2C19 *1/*2 + *1/*8 + *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) .
Notes: Active metabolite exposure was significantly lower with PM than with EM.  Patients were also treated with aspirin.   There were 37 EM (by genotype) and 9 PM (by genotype).  Dosage was 600 mg loading/75 mg maintenance.
Article: Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome
Gene: ABCB1
Variant/haplotype: rs2032582
Drug(s): tacrolimus
Phenotype category: Efficacy
Significant: yes
Association: Genotypes AA + TT is associated with increased response to tacrolimus in people with Nephrotic Syndrome as compared to genotypes CC + CT.
Notes: Patients with the AA, AT or TT genotype had a higher effectiveness of clinical treatment as compared to those with the CT, AC or CC genotypes. Effective response included patients with complete or partial remission, and ineffective response included patients with no remission or recurrence. Please note that alleles have been complemented to the plus chromosomal strand.
Article: Association studies of dopamine synthesis and metabolism genes with multiple phenotypes of heroin dependence
Gene: SLC6A3
Variant/haplotype: rs6347
Drug(s): heroin
Phenotype category: Efficacy
Significant: no
Association: Allele C is not associated with response to heroin as compared to allele T.
Notes: No significant association between this variant and strength of euphoria on first heroin use.
Article: The Effects of Inherited NUDT15 Polymorphisms on Thiopurine Active Metabolites in Japanese Children with Acute Lymphoblastic Leukemia
Gene: NUDT15
Variant/haplotype: NUDT15*1, NUDT15*2, NUDT15*3
Drug(s): mercaptopurine
Phenotype category: Toxicity
Significant: yes
Association: NUDT15 *2/*3 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.
Notes: The mean mercaptopurine (MP) dosages were 48.0 ± 21.2, 34.1 ± 17.0, and 3.2 ± 1.2 mg/m2 for the normal-activity (*1/*1 n=44), intermediate-activity (*1/*2 + *1/*3 + *1/*5 n=10), and low-activity (*2/*3 n=1) NUDT15 groups, respectively (P =4.8×10-4). TGN (thioguanine nucleotides, not further specified) levels was correlated negatively with the number of NUDT15 risk alleles (P=5.3×10-6) and this association remained significant after adjusting for MP dosage (P = 1.7 × 10 - 6). The ratio of DNA-TG to TGN (i.e. the percent of TGN converted to DNA-TG) was significantly higher in NUDT15-deficient patients (P=3.6× 10 - 9).
Article: Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics: A Pilot Study
Gene: CYP2D6
Variant/haplotype: CYP2D6*1, CYP2D6*9
Drug(s): fentanyl
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP2D6 *9 is associated with decreased clearance of fentanyl in people with Burns as compared to CYP2D6 *1.
Notes: Single patient identified with the CYP2D6*9 allele. Clearance of fentanyl in this patient was significantly lower than in WT patients.
Article: The Effect of CYP2D6 polymorphisms on the Response to Pain Treatment for Pediatric Sickle Cell Pain Crisis
Gene: CYP2D6
Variant/haplotype: CYP2D6*1, CYP2D6*17
Drug(s): codeine
Phenotype category: Efficacy
Significant: yes
Association: CYP2D6 *17 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.
Notes: Pediatric patients with severe sickle cell disease who have failed codeine therapy for a pain crisis while taking hydroxyurea were found to be more likely to have a reduced function allele (including *4, *5, *6, *17, *40) as compared to those with mild disease, likely due to a decreased conversion of codeine to morphine. Allele frequencies were not reported. Reduced function alleles were grouped for analysis.
Article: Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study
Gene: TXNDC11
Variant/haplotype: rs3784921
Drug(s): hydrochlorothiazide
Phenotype category: Efficacy
Significant: yes
Association: Allele G is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to allele T.
Notes: The G allele was associated with a reduced systolic blood pressure response to hydrochlorothiazide.
Article: Association studies of dopamine synthesis and metabolism genes with multiple phenotypes of heroin dependence
Gene: SLC6A3
Variant/haplotype: rs10064525
Drug(s): heroin
Phenotype category: Dosage
Significant: no
Association: Allele G is not associated with dose of heroin in people with Heroin Dependence as compared to allele T.
Article: Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway
Gene: CRH
Variant/haplotype: rs4737771
Drug(s): antidepressants
Phenotype category: Efficacy
Significant: yes
Association: Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T.
Notes: Identity of minor allele not specified, so minor allele of dbSNP used here (C). Remission considered to be score < or equal to 7 at discharge of the Hamilton Rating Scale for Depression (HRSD17). Patients measured at admission and discharge, 4-6 weeks later. Specific antidepressants not listed.
Article: Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients
Gene: ERCC1
Variant/haplotype: rs3212986
Drug(s): Platinum compounds
Phenotype category: Efficacy
Significant: no
Association: Allele C is not associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.
Notes: No significant relationship between genotype and drug response was detected.
Article: Association and cis-mQTL analysis of variants in CHRNA3-A5, CHRNA7, CHRNB2, and CHRNB4 in relation to nicotine dependence in a Chinese Han population
Gene: CHRNB4
Variant/haplotype: rs950776
Drug(s): nicotine
Phenotype category: Other
Significant: no
Association: Allele C is not associated with exposure to nicotine in men as compared to allele T.
Notes: No significant association between this allele and status as a smoker or non-smoker.
Article: Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections
Gene: CYP2C19
Variant/haplotype: CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17
Drug(s): voriconazole
Phenotype category: Metabolism/PK
Significant: yes
Association: CYP2C19 *1/*2 + *1/*3 + *2/*17 is associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.
Notes: Patients who were intermediate metabolizers (*1/*2, *1/*3 or *2/*17) had increased trough concentrations (C0) and dose-adjusted trough concentrations (C0/D) as compared to those who were normal metabolizers (*1/*1). However, when each genotype was assessed separately (*1/*2 vs *1/*1 and *1/*3 vs *1/*1), no significant association was found for C0 or C0/D.
Article: Effects of UGT1A1 Genotype on the Pharmacokinetics, Pharmacodynamics, and Toxicities of Belinostat Administered by 48-Hour Continuous Infusion in Patients With Cancer
Gene: UGT1A1
Variant/haplotype: UGT1A1*1, UGT1A1*60
Drug(s): belinostat
Phenotype category: Metabolism/PK
Significant: yes
Association: UGT1A1 *1/*60 + *60/*60 is associated with decreased metabolism of Belinostat in people with Neoplasms.
Notes: Belinostat half-life time was increased in carriers of the *60 allele (*1/*60 n=11, *60/*60 n=5) as compared to those with the *1/*1 genotype. Significant results were also seen when only including patients who received a belinostat dose greater than 400 mg/m2/24h (*1/*60 n=7; *60/*60 n=4). No significant association was seen for AUC, Cmax or clearance. Patients received belinostat in combination with cisplatin and etoposide. p < 0.01 was considered statistically significant.
Article: Genome-wide association study of patient and clinician rated global impression severity during antipsychotic treatment
Gene: TJP1
Variant/haplotype: rs711355
Drug(s): risperidone
Phenotype category: Efficacy
Significant: yes
Association: Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.
Notes: The number of T alleles present in a patient was negatively associated with PGI score. Please note that this variant is in high linkage disequilibrium with rs785423 and rs813676.
Article: Association studies of dopamine synthesis and metabolism genes with multiple phenotypes of heroin dependence
Gene: SLC6A3
Variant/haplotype: rs1042098
Drug(s): heroin
Phenotype category: Efficacy
Significant: no
Association: Allele G is not associated with response to heroin as compared to allele A.
Notes: No significant association between this variant and strength of euphoria on first heroin use.